Atlantic Coast Consortium for Asthma (ACC-A) AsthmaNet Clinical Site

描述（由申请人提供）：为了响应AsthmaNet RFA，我们已经建立了大西洋海岸哮喘联盟（ACC-A）作为临床站点。它由维克森林大学健康科学（SP Peters， PI，首席研究员，成人）、弗吉尼亚大学（WG Teague, Co-PI，首席研究员，儿童）、埃默里大学（A Fitzpatrick, Co-I，现场主任）和北卡罗来纳州临床研究（C LaForce, Co-I，医学主任）组成。该研究小组在国家哮喘网络（包括哮喘临床研究网络（ACRN） 1和2、严重哮喘研究计划（SARP）、美国肺脏协会哮喘临床研究中心（ALA-ACRC）、哮喘流行病学和自然史）中作为参与者和主要研究者具有丰富的经验。结果和治疗方案（TENOR）项目，以及现有流行病学数据（STAMPEED，哮喘和肺功能基因组广泛关联）中与多种表型相关的SNP分型，以及各种哮喘临床试验。凭借这些经验和广泛的资源，我们同意参与AsthmaNet的各个方面，并提出两个主要方案（附带探索性和机械性方案），重点关注成人和儿童严重哮喘的特定亚群。基于基因的抗TNF治疗严重哮喘（Gene BATTS）是一项随机、双盲、安慰剂对照的成人基因型分层试验，旨在验证具有肿瘤坏死因子（TNF）受体基因特异性遗传变异的严重哮喘患者比没有这些变异的患者对抗TNF的反应更好的假设。儿童严重哮喘的管理选择（MOSAIC）是一项随机、双盲、平行组试验，旨在确定3种治疗方案的疗效：单独880 meg/天氟替卡松、440 meg/天氟替卡松+ BID沙美特罗和440 meg/天氟替卡松+ BID异丙托溴铵在氟替卡松440 meg/天控制不充分的严重哮喘儿童中的疗效。伴随方案将检查成人皮质类固醇耐药（RASS）和可能的耐药遗传机制（IMMOST），以及儿童吸入s -亚硝基谷胱甘肽（N30-201） （SNORT）的疗效。

DESCRIPTION (provided by applicant): In response to the AsthmaNet RFA, we have established the Atlantic Coast Consortium for Asthma (ACC-A) to serve as a clinical site. It consists of Wake Forest University Health Sciences (SP Peters, PI, Lead Investigator, Adults), University of Virginia (WG Teague, Co-PI, Lead Investigator, Children), Emory University (A Fitzpatrick, Co-I, Site Director), and North Carolina Clinical Research (C LaForce, Co-I, Medical Director). The group of investigators assembled has extensive experience as participants and lead investigators in national asthma networks including the Asthma Clinical Research Network (ACRN) 1 and 2, the Severe Asthma Research Program (SARP), the American Lung Association's Asthma Clinical Research Centers (ALA-ACRC), The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) program, and SNP Typing for Association with Multiple Phenotypes from Existing Epidemiologic Data (STAMPEED, Genome wide Association for Asthma and Lung Function), and with a wide variety of asthma clinical trials. With this experience and extensive resources, we agree to participate in all aspects of AsthmaNet and propose two major protocols (with companion exploratory and mechanistic protocols) focusing on specific sub-sets of severe asthmatics in adults and children. Gene-Based Anti-TNF Therapy in Severe Asthma (Gene BATTS) is a randomized, double-blind, placebo-controlled genotype-stratified trial in adults designed to test the hypothesis that severe asthmatics with specific genetic variants in tumor necrosis factor (TNF) receptor genes respond better to anti-TNF than patients without these variants. Management Options for Severe Asthma in Children (MOSAIC) is a randomized, double-blinded, parallel group trial designed to determine the efficacy of 3 treatment regimes: 880 meg/day fluticasone alone, 440 meg/day fluticasone + BID salmeterol, and 440 meg/day fluticasone + BID ipratropium bromide in severe asthmatic children inadequately controlled on fluticasone 440 meg/day. Companion protocols will examine corticosteroid resistance (RASS) and a possible genetic mechanism for resistance (IMMOST) in adults, and the efficacy of inhaled S-nitrosoglutathione (N30-201) (SNORT) in children.